John Johnson - Net Worth and Insider Trading

John Johnson Net Worth

The estimated net worth of John Johnson is at least $5 Million dollars as of 2026-09-11. John Johnson is the Director of Xeris Biopharma Holdings Inc and owns about 707,276 shares of Xeris Biopharma Holdings Inc (XERS) stock worth over $5 Million. John Johnson is the CEO of Melinta Therapeutics Inc and owns about 37,400 shares of Melinta Therapeutics Inc (MLNTQ) stock worth over $4,114. John Johnson is also the Director of Axogen Inc and owns about 0 shares of Axogen Inc (AXGN) stock worth over $0. Details can be seen in John Johnson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Johnson has not made any transactions after 2026-06-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of John Johnson

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

XERS Xeris Biopharma Holdings Inc

100% of holdings · $5.4M

MLNTQ Melinta Therapeutics Inc

John Johnson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Johnson owns 12 companies in total, including Portola Pharmaceuticals Inc (PTLA) , Strongbridge Biopharma PLC (SBBP) , and Verastem Inc (VSTM) among others .

Click here to see the complete history of John Johnson’s form 4 insider trades.

Insider Ownership Summary of John Johnson

Ticker	Company	Transaction Date	Type of Owner
PTLA	Portola Pharmaceuticals Inc	2020-07-02	director
SBBP	Strongbridge Biopharma PLC	2020-07-02	director & Chief Executive Officer
VSTM	Verastem Inc	2020-06-16	director
		2019-06-27	director & Chief Executive Officer
		2016-12-16	director
		2018-02-13	director
		2018-02-01	director
		2012-08-07	director
		2009-11-01	Sr. VP & Oncology Business Unit
		2026-05-07	director
		2026-06-04	director
		2024-12-19	director & Executive Chairman

John Johnson Latest Holdings Summary

John Johnson currently owns a total of 3 stocks. Among these stocks, John Johnson owns 707,276 shares of Xeris Biopharma Holdings Inc (XERS) as of June 4, 2026, with a value of $5 Million and a weighting of 99.92%. John Johnson owns 37,400 shares of Melinta Therapeutics Inc (MLNTQ) as of June 27, 2019, with a value of $4,114 and a weighting of 0.08%. John Johnson also owns 0 shares of Axogen Inc (AXGN) as of May 7, 2026, with a value of $0 and a weighting of 0%.

Latest Holdings of John Johnson

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XERS	Xeris Biopharma Holdings Inc	2026-06-04	707,276	7.66	5,417,734
MLNTQ	Melinta Therapeutics Inc	2019-06-27	37,400	0.11	4,114
AXGN	Axogen Inc	2026-05-07	0	41.83	0

Holding Weightings of John Johnson

John Johnson Form 4 Trading Tracker

According to the SEC Form 4 filings, John Johnson has made a total of 3 transactions in Xeris Biopharma Holdings Inc (XERS) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Xeris Biopharma Holdings Inc is the sale of 15,000 shares on June 4, 2026, which brought John Johnson around $91,350.

According to the SEC Form 4 filings, John Johnson has made a total of 0 transactions in Melinta Therapeutics Inc (MLNTQ) over the past 5 years. The most-recent trade in Melinta Therapeutics Inc is the sale of 13,000 shares on June 27, 2019, which brought John Johnson around $72,410.

According to the SEC Form 4 filings, John Johnson has made a total of 3 transactions in Axogen Inc (AXGN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Axogen Inc is the sale of 11,050 shares on May 7, 2026, which brought John Johnson around $478,023.

Insider Trading History of John Johnson

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Johnson Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock John Johnson owns.

- XERS - MLNTQ - AXGN

View XERS Analysis

John Johnson Ownership Network

Ownership Network List of John Johnson

No Data

Ownership Network Relation of John Johnson

John Johnson Owned Company Details

What does Portola Pharmaceuticals Inc do?

Who are the key executives at Portola Pharmaceuticals Inc?

John Johnson is the director of Portola Pharmaceuticals Inc. Other key executives at Portola Pharmaceuticals Inc include EVP & General Counsel John B Moriarty , EVP and CFO Mardi Dier , and EVP & CMO Rajiv Patni .

Portola Pharmaceuticals Inc (PTLA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Portola Pharmaceuticals Inc (PTLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Portola Pharmaceuticals Inc (PTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Portola Pharmaceuticals Inc (PTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Portola Pharmaceuticals Inc Insider Transactions

No Available Data

What does Strongbridge Biopharma PLC do?

Who are the key executives at Strongbridge Biopharma PLC?

John Johnson is the director & Chief Executive Officer of Strongbridge Biopharma PLC. Other key executives at Strongbridge Biopharma PLC include 10 percent owner Cdk Associates, L.l.c. , 10 percent owner Caxton Corp , and 10 percent owner Bruce Kovner .

Strongbridge Biopharma PLC (SBBP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Strongbridge Biopharma PLC (SBBP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Strongbridge Biopharma PLC (SBBP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Strongbridge Biopharma PLC (SBBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Strongbridge Biopharma PLC Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

John Johnson is the director of Verastem Inc. Other key executives at Verastem Inc include Chief Operating Officer Dan Paterson , Vice President of Finance Daniel Calkins , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, John Johnson made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 145,568 shares made by Dan Paterson , a net sale of 24,659 shares made by Daniel Calkins , and a net sale of 2,366 shares made by Brian M Stuglik .

In summary, during the past 3 months, insiders sold 26,262 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 26,262 shares. During the past 18 months, 196,858 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 196,858 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does Melinta Therapeutics Inc do?

Who are the key executives at Melinta Therapeutics Inc?

John Johnson is the director & Chief Executive Officer of Melinta Therapeutics Inc. Other key executives at Melinta Therapeutics Inc include director & See Remarks Daniel Mark Wechsler , Chief Commercial Officer John Temperato , and director & President and CEO Prabhavathi Fernandes .

Melinta Therapeutics Inc (MLNTQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Melinta Therapeutics Inc (MLNTQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Melinta Therapeutics Inc (MLNTQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Melinta Therapeutics Inc (MLNTQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Melinta Therapeutics Inc Insider Transactions

No Available Data

What does Ocugen Inc do?

Who are the key executives at Ocugen Inc?

John Johnson is the director of Ocugen Inc. Other key executives at Ocugen Inc include Chief Financial Officer Treerita Essalima Johnson-greene , Chief Accounting Officer Ramesh Ramachandran , and Chief Medical Officer Huma Qamar .

Ocugen Inc (OCGN) Insider Trades Summary

Over the past 18 months, John Johnson made no insider transaction in Ocugen Inc (OCGN). Other recent insider transactions involving Ocugen Inc (OCGN) include a net purchase of 21,000 shares made by Treerita Essalima Johnson-greene ,

In summary, during the past 3 months, insiders sold 0 shares of Ocugen Inc (OCGN) in total and bought 21,000 shares, with a net purchase of 21,000 shares. During the past 18 months, 0 shares of Ocugen Inc (OCGN) were sold and 21,000 shares were bought by its insiders, resulting in a net purchase of 21,000 shares.

Ocugen Inc (OCGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocugen Inc Insider Transactions

No Available Data

What does Sucampo Pharmaceuticals Inc do?

Who are the key executives at Sucampo Pharmaceuticals Inc?

John Johnson is the director of Sucampo Pharmaceuticals Inc. Other key executives at Sucampo Pharmaceuticals Inc include Chief Executive Officer Peter Greenleaf , CFO Peter P. Pfreundschuh , and Chief Science Officer Peter A Kiener .

Sucampo Pharmaceuticals Inc (SCMP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sucampo Pharmaceuticals Inc (SCMP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sucampo Pharmaceuticals Inc (SCMP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sucampo Pharmaceuticals Inc (SCMP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sucampo Pharmaceuticals Inc Insider Transactions

No Available Data

What does AVEO Pharmaceuticals Inc do?

Who are the key executives at AVEO Pharmaceuticals Inc?

John Johnson is the director of AVEO Pharmaceuticals Inc. Other key executives at AVEO Pharmaceuticals Inc include Chief Operating Officer Jebediah Ledell , director & President & CEO Michael P Bailey , and Chief Commercial Officer Michael Ferraresso .

AVEO Pharmaceuticals Inc (AVEO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AVEO Pharmaceuticals Inc (AVEO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AVEO Pharmaceuticals Inc (AVEO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AVEO Pharmaceuticals Inc (AVEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

AVEO Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ocera Therapeutics Inc do?

Who are the key executives at Ocera Therapeutics Inc?

John Johnson is the director of Ocera Therapeutics Inc. Other key executives at Ocera Therapeutics Inc include 10 percent owner Brian H Dovey , 10 percent owner Domain Partners Viii, L.p. , and 10 percent owner Dp Viii Associates, L.p. .

Ocera Therapeutics Inc (OCRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ocera Therapeutics Inc (OCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ocera Therapeutics Inc (OCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ocera Therapeutics Inc (OCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocera Therapeutics Inc Insider Transactions

No Available Data

What does Eli Lilly and Co do?

Who are the key executives at Eli Lilly and Co?

John Johnson is the Sr. VP & Oncology Business Unit of Eli Lilly and Co. Other key executives at Eli Lilly and Co include SVP and Pres. & Lilly Bio-Meds Patrik Jonsson , Chief Accounting Officer Donald A Zakrowski , and Senior VP & General Counsel Anat Hakim .

Eli Lilly and Co (LLY) Insider Trades Summary

Over the past 18 months, John Johnson made no insider transaction in Eli Lilly and Co (LLY). Other recent insider transactions involving Eli Lilly and Co (LLY) include a net sale of 4,034,408 shares made by Lilly Endowment Inc , a net sale of 6,000 shares made by Donald A Zakrowski , and a net sale of 5,000 shares made by Ilya Yuffa .

In summary, during the past 3 months, insiders sold 13,500 shares of Eli Lilly and Co (LLY) in total and bought 0 shares, with a net sale of 13,500 shares. During the past 18 months, 4,056,908 shares of Eli Lilly and Co (LLY) were sold and 6,987 shares were bought by its insiders, resulting in a net sale of 4,049,921 shares.

Eli Lilly and Co (LLY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eli Lilly and Co Insider Transactions

No Available Data

What does Axogen Inc do?

Who are the key executives at Axogen Inc?

John Johnson is the director of Axogen Inc. Other key executives at Axogen Inc include EVP & General Counsel Marc A Began , Chief Marketing Officer Jens Kemp , and CFO Lindsey Marie Hartley .

Axogen Inc (AXGN) Insider Trades Summary

Over the past 18 months, John Johnson made 3 insider transaction in Axogen Inc (AXGN) with a net sale of 60,502. Other recent insider transactions involving Axogen Inc (AXGN) include a net sale of 136,536 shares made by Burke William P. Mr. , a net sale of 78,126 shares made by Joseph A. Tyndall , and a net sale of 81,220 shares made by Kathy Johnson Weiler .

In summary, during the past 3 months, insiders sold 98,503 shares of Axogen Inc (AXGN) in total and bought 0 shares, with a net sale of 98,503 shares. During the past 18 months, 712,419 shares of Axogen Inc (AXGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 712,419 shares.

Axogen Inc (AXGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axogen Inc Insider Transactions

No Available Data

What does Xeris Biopharma Holdings Inc do?

Who are the key executives at Xeris Biopharma Holdings Inc?

John Johnson is the director of Xeris Biopharma Holdings Inc. Other key executives at Xeris Biopharma Holdings Inc include See Remarks Kevin Mcculloch , Chief Financial Officer Steven Pieper , and See Remarks Beth Hecht .

Xeris Biopharma Holdings Inc (XERS) Insider Trades Summary

Over the past 18 months, John Johnson made 3 insider transaction in Xeris Biopharma Holdings Inc (XERS) with a net sale of 257,900. Other recent insider transactions involving Xeris Biopharma Holdings Inc (XERS) include a net sale of 223,334 shares made by Beth Hecht , a net sale of 110,000 shares made by Kevin Mcculloch , and a net sale of 55,000 shares made by Steven Pieper .

In summary, during the past 3 months, insiders sold 224,998 shares of Xeris Biopharma Holdings Inc (XERS) in total and bought 0 shares, with a net sale of 224,998 shares. During the past 18 months, 896,949 shares of Xeris Biopharma Holdings Inc (XERS) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 871,949 shares.

Xeris Biopharma Holdings Inc (XERS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xeris Biopharma Holdings Inc Insider Transactions

No Available Data

What does Applied Therapeutics Inc do?

Who are the key executives at Applied Therapeutics Inc?

John Johnson is the director & Executive Chairman of Applied Therapeutics Inc. Other key executives at Applied Therapeutics Inc include Chief Medical Officer Evan Prescott Bailey , Chief Commercial Officer Hooks Corwin Dale , and Chief Medical Officer Riccardo Perfetti .

Applied Therapeutics Inc (APLT) Insider Trades Summary

Over the past 18 months, John Johnson made no insider transaction in Applied Therapeutics Inc (APLT). Other recent insider transactions involving Applied Therapeutics Inc (APLT) include a net sale of 43,000 shares made by Stacy J. Kanter ,

In summary, during the past 3 months, insiders sold 0 shares of Applied Therapeutics Inc (APLT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 43,000 shares of Applied Therapeutics Inc (APLT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 43,000 shares.

Applied Therapeutics Inc (APLT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Applied Therapeutics Inc Insider Transactions

No Available Data

John Johnson Mailing Address

Above is the net worth, insider trading, and ownership report for John Johnson. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, John Johnson's mailing address is: Seattle Wa 98101.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.